100s of titles, one news app for just $10 a month.
Dive Deeper:
Get all your news in one place
Latest National news:
Abbey Harkin named in Australian swim team for world titles and Commonwealth Games
She is among 39 athletes selected.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Australia election 2022 live: Anthony Albanese to be sworn in as prime minister; Labor inches towards majority government
Follow all the day’s developments
Floriade to return to traditional home after two years
The festival will begin in September and run through to October.
Election 2022: Early rush to pre-poll was a sign of the obvious as voters embrace Labor and change
Election 2022: Labor in charge as Morrison era ends
Stoking fear and hatred held the Coalition in power – finally Australia had enough
For the first time in a decade the logjam to change the country’s politics may be shifting
From analysis to good news, read the world’s best news in one place
George Thorogood is coming to Newcastle
"Expect our best on this tour because that's what you're gonna get."
Michael McCormack suggests Barnaby Joyce’s unpopularity in inner-city contributed to Coalition’s loss
Former Nationals leader says he was ‘very popular’ in inner city and that mixed messages on net zero emissions ‘didn’t…

State sues Teva over Copaxone drug royalties

By YONAH JEREMY BOB
Photo by: SIVAN FARAG

The state filed a lawsuit against pharmaceutical giant Teva for NIS 340 million on Wednesday, over royalties relating to its star medical drug for multiple sclerosis known as Copaxone.

According to the lawsuit brought in Lod District Court, Teva had a patent for Copaxone from 1996 until 2014, and then put out a new updated version leading up to the expiration of the patent in 2014.

That updated version instructed taking the medicine three times a week and at a higher dosage, instead of on a daily basis.

The state said that significant aspects of the research that led to the issuing of the updated version came out of state-funded researchers and medical centers, including Prof. Amos Corchin from Ichilov Medical Center and Dr. Shlomo Flechter from Assaf Harofeh Medical Center.

The two doctors sued Teva for failing to acknowledge their contributions, and demanded to be compensated with royalties stemming from the new version of Copaxone.

A building in Jerusalem belonging to generic drug producer Teva (credit: REUTERS/BAZ RATNER)

In Wednesday’s lawsuit, the state accused Teva of hiding from the government that it had rights to royalties from the new version. According to the lawsuit, the state learned that its rights to royalties were being violated only after learning of the lawsuit filed by the two medical researchers in 2018.

The state’s lawsuit preemptively addresses defenses that Teva has already made in the 2018 lawsuit, claiming that the research of the two medical centers was qualitatively different from the research that led to producing the new Copaxone.

The state said that the differences in the research from the state medical centers compared with other research that Teva was involved in were extremely small and insignificant.

Moreover, the state noted that Teva itself cited the research from the two medical centers in its application for a new patent to the US Food and Drug Administration.

According to the state, this citation in and of itself proved the critical contribution of state-funded research both to developing the new drug and to getting the new drug approved by the FDA.

Teva reported last week that its revenue for the first quarter of 2022 was $3.7 billion. It is thought that the lawsuit could have a considerable impact but is not likely to raise questions about its long-term stability.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.